Posted at 11:21 p.m. on Feb. 23, 2009

Monday was another ugly day on Wall Street as markets tumbled to their lowest close in 12 years.

While bank stocks took a brief reprieve from their seemingly daily dive down, the mood created by the financial crisis permeated other sectors, naming technology, materials and industrials.

Technology stocks led the decline with IBM (IBM) falling 5% on concerns of lower capital spending. Microsoft (MSFT), Apple (AAPL) and Intel (INTC) also contributed significantly to the market retreat.

With this in mind, we thought we'd take a look at some of the stocks people have been searching for on and see what Jim Cramer's had to say about them lately.

These stocks could be in the news for a number of reasons. Some require immediate attention while others may not. Regardless, it never hurts to hear what Cramer (or any of the other professional investors on the site) has to say about them. The key is to gather as much information as you can in order to make the most informed investment decisions you can.

In a recent post to his RealMoney blog, Cramer had this to say about Cephalon (CEPH) and other biotechs:

"Maybe the difficulty in reconciling Helene Meisler's view on the Nasdaq to Doug Kass's view on the Nasdaq is biotech!

"Helene doesn't like the Nazz, thinks it is about to roll over. Doug's on board -- he likes the action and is long.

"Perhaps the difference in views is that I am thinking of this index as tech when I should be thinking of it as biotech -- namely Cephalon, Genzyme (GENZ), Celgene (CELG), Gilead (GILD), Biogen (BIB), Amgen (AMGN) and Sepracor (SEPR) plus a bunch of other health care players.

"The Nazz has the benefits of almost no banks, lots of techs with big cash positions and these biotech wonders that have acted fabulously since the year began.

"Sometimes an index isn't what it seems. The biotechs, subliminally, may be the reason why the Nasdaq rallied even on this awful day. I predict continued outperformance by biotech in this world of zero interest rates. So, tie goes to Dougie!"

For more of what Cramer's had to say about Monday's top-searched stocks, including Starbucks (SBUX), Barclays (BCS) and Dominion Resourcs (D), check out the Cramer's Take portfolio on Stockpickr.

(Editor's note: At the time of publication and/or original publication of his posts and shows, Cramer owned Gilead and Celgene for his Action Alerts PLUS charitable trust.)

P.S. Where is Cramer putting his own money? Take a free peek at his personal portfolio to see all his buys and sells by clicking here. When you do, Jim will also send you exclusive email alerts telling you everything he's about to add to or shed from his Action Alerts PLUS portfolio -- before he makes his trade.